Patients with ED exhibit varying treatment patterns across races
“More research needs to be done, but I think this is something that gets the conversation started,” says Tony Chen, MD.
In this video, Tony Chen, MD, discusses the study, “Associations between Race and Erectile Dysfunction Treatment Patterns,” and how it contributes to the conversation of racial disparities within the health care system. This study was presented at the 2021 American Urological Association Annual Meeting. Chen is a clinical assistant professor of urology at Stanford University, California.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
